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Objectives: The CFTR2 Database considers the class IV CFTR mutation R117C
(c.349C>T) to be a disease causing mutation. However, the clinical importance
is difﬁcult to determine due to its rareness. This report describes the ﬁrst case
of R117C homozygosity, by maternal uniparental isodisomy (UPD) causing cystic
ﬁbrosis (CF) and Silver–Russell syndrome.
Methods: Clinical description, genetic diagnosis, nasal potential difference (NPD).
Results: A 17 months old boy was referred to our CF Centre as a part of the
investigation of failure to thrive. Height and weight was within normal variation
at birth but decreased to −4SD. The history revealed recurrent upper respiratory
tract infections, but no pneumonias, normal stools. Exams showed: Sweat Cl−
(Gibson): 54 and 64mmol/L, chest radiogram: bronchial thickening, pulmonary
function test: Vmax FRC 275 (+0.2 SD), anti-S. aureus and P. aeruginosa: negative,
F-chymotrypsine and -elastase: normal. DNA sequence analysis showed that the
mother was a carrier of R117C (IVS-8 7T). No sequence change could be detected
in the father. Microsatellites covering chromosome 7 showed maternal UPD of
chromosome 7. NPD showed borderline pathology. Patient outcome up to 6 years
of age: Sweat Cl−: 92 and 75mmol/L. Chest radiogram: bronchial thickening
w/o bronchiectasis. Pulmonary function test: Vmax FRC 335 (−0.3 SD) at 3 yrs
and FEV1 0.61 L (58%) at 6 yrs. Occasional cultures of Haemophilus inﬂuenzae
and Moraxella catarrhalis. Anti-S. aureus and P. aeruginosa: negative. F-elastase:
normal. The patient has intermittent need of inhalation therapy.
Conclusion: The clinical manifestations and the NPD result for mutation R117C
are non classical.
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Ivacaftor is approved for the treatment of CF patients (pts) 6 years who have
a G551D-CFTR mutation. In vitro, ivacaftor increased chloride transport through
CFTR channels with mutations associated with residual function, such as R117H .
KONDUCT evaluated the efﬁcacy and safety of ivacaftor in CF pts with R117H-
CFTR.
KONDUCT was a Phase 3, randomized, double-blind, placebo-controlled study.
69 pts 6 years, with R117H and FEV1 40% of predicted, were randomized and
dosed to ivacaftor 150mg or placebo q12h for 24 weeks. The primary endpoint
was absolute change in %predicted FEV1 through Week 24. Secondary measures
included sweat chloride, BMI, respiratory domain of the CF Questionnaire-Revised
(CFQ-R; MCID, 4.0) and safety.
Through Week 24, the treatment difference in mean absolute change from baseline
in %predicted FEV1 between ivacaftor and placebo groups was 2.1 percentage
points (p = 0.20, NS). Treatment with ivacaftor resulted in treatment differences
in CFQ-R (+8.4, p = 0.009) and sweat chloride (−24.0mmol/L, p< 0.001). BMI
treatment difference was not signiﬁcant (+0.26 kg/m2, p = 0.78). In pre-speciﬁed
age subgroup analyses, the treatment difference in absolute change in %predicted
FEV1 for age 18 (n = 50, baseline FEV1 = 64.5%) was +5.0 percentage points
(p = 0.01) and −6.3 percentage points (p = 0.03) for pts ages 6−11 (n = 17, baseline
FEV1 = 95.8%). No new safety concerns were identiﬁed. Serious AEs were reported
by 6 pts (placebo) and 4 (ivacaftor); pulmonary exacerbation was the most common
SAE.
Although the study did not meet the primary endpoint, secondary endpoints and
subgroup analyses suggest that ivacaftor may beneﬁt some pts with R117H-CFTR,
particularly those aged 18.
